Are We There Yet? Researchers Differ on When a Genome Sequence Is Complete

if (n == null) The Scientist - Are We There Yet? Researchers Differ on When a Genome Sequence Is 'Complete' The Scientist 13[15]:12, Jul. 19, 1999 News Are We There Yet? Researchers Differ on When a Genome Sequence Is Complete By: Karen Hopkin A great deal of fanfare and much celebration greeted the publication of the C. elegans sequence in Science this past December.1,2 "Caenorhabditis elegans made it big today as Human Genome Project researchers in

Written byKaren Hopkin
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share


News

A great deal of fanfare and much celebration greeted the publication of the C. elegans sequence in Science this past December.1,2 "Caenorhabditis elegans made it big today as Human Genome Project researchers in the United States and Great Britain announced they have sequenced the animal's 97 million-base genome," stated the official press release distributed by the National Human Genome Research Institute (NHGRI). And Science's table of contents touted its special section commemorating "the completion of the genome sequence for C. elegans."

But is the worm sequence really complete? It all depends on what you mean by complete. "At some level it's a little arbitrary when you declare a sequence essentially complete," says NHGRI Director Francis Collins. And the worm sequence contained 100 or so hard-to-fill gaps when it was unveiled--about 70 of which continue to vex sequencers.

Now the sequencing community is beginning to discuss just what it ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies